Mereo BioPharma (MREO) CFO Christine Fox Receives Equity Award

What Happened
Christine Ann Fox, Chief Financial Officer of Mereo BioPharma Group plc (MREO), received three equity awards (classified as derivative securities) on February 1, 2026 totaling 701,000 shares: 315,750; 105,250; and 280,000. Each grant is reported at $0.00 per share (no purchase price shown). These are awards/grants (code A), not open‑market purchases or sales — they represent compensation subject to vesting rather than an immediate investment or divestment.

Key Details

• Transaction date: February 1, 2026 (reported on Form 4 filed Feb 2, 2026 — timely filing).
• Grants: 315,750; 105,250; and 280,000 derivative shares; all reported at $0.00 per share. Total = 701,000 shares.
• Shares owned after transaction: Not specified in the summary provided. (Check full Form 4 for total beneficial ownership.)
• Footnotes in filing:
  • F1: 25% of one grant vests Feb 1, 2027, remainder vests in equal monthly installments over the next three years.
  • F3: One grant vests in substantially equal monthly installments over one year from Feb 1, 2026.
  • F2: Each American Depositary Share (ADS) equals five ordinary shares (filing notes ADS/ordinary share relationship).
• No 10b5‑1 plan or tax‑withholding/cashless exercise details are indicated in the provided summary.

Context
These are compensation awards (derivative securities) that vest over time — they do not represent an immediate purchase of shares that would signal a current market bet. Awards with $0.00 reported price typically mean the insider will receive or be able to acquire ordinary shares/ADS subject to the listed vesting schedules. For retail investors, such grants are common for executives and are primarily an employment/retention matter rather than a direct buy or sell signal.